Session » SLE – Diagnosis, Manifestations, & Outcomes III: Lupus Nephritis (1512–1516)

Date: Sunday, November 8, 2020

Time: 4:00PM-4:50PM

Meeting: ACR Convergence 2020

4:00PM-4:50PM: Abstract Number: 1515

Renal Responder Status and Associated Clinical Variables in the Lupus Accelerating Medicines Partnership Cohort

4:00PM-4:50PM: Abstract Number: 1513

Role of Platelet C4d in Thrombosis and Lupus Nephritis

4:00PM-4:50PM: Abstract Number: 1514

The Impact of Renal Transplantation on Cardiovascular Events Among Patients with End-State Kidney Disease Due to Lupus Nephritis: A Nationwide Cohort Study

4:00PM-4:50PM: Abstract Number: 1516

The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership

4:00PM-4:50PM: Abstract Number: 1512

Trajectory Analysis of Repeat Renal Biopsies Identified Previous Endocapillary Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Nephritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].